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Background/aim:  Ulcerative  colitis  (UC)  patients  are  at increased  risk  for colorectal  carci-
noma (CRC).  It is suggested  that  cyclooxygenase-2  (COX-2)  plays  a  role  in sporadic  CRC.
The p53  gene  is  a tumor-suppressor  gene  and  the  most  frequent  site  of genetic  alteration
found  in  human  cancer.  The  aim  of  this  study  was to analyze  the  immunoexpression  of
proinﬂammatory  enzyme  COX-2  and  p53  in  UC, UC-associated  dysplasia,  and  CRC, in  com-
parison  with  each  other  and  with  different  clinical  and  histopathological  parameters,  to
clarify  if they  have  a  possible  role  in  the  pathogenesis  of CRC  in  UC  patients.
Materials  and  methods:  In this  cross-sectional  study,  98  patients  were  divided  into  three
groups:  39 patients  with  UC  without  dysplasia,  32 patients  with  UC with  dysplasia,  and 27
patients with  colorectal  cancer  on top  of UC,  in  addition  to 10 healthy  controls.  All patients
underwent  colonoscopy,  and  multiple  biopsies  were  taken for  histopathological  and  COX-2
and p53  immunohistochemical  studies.
Results:  There  was signiﬁcant  difference  in  the  expression  of  COX-2  and  p53 in  UC-related
dysplasia  either  without  or  with  CRC,  compared  with  their  expression  in  the UC  group
without  dysplasia.
Conclusion:  Adding  immunohistochemical  analysis  of COX-2  enzyme  and  p53  gene  to rou-
tine histological  assessment  may  improve  the  accuracy  of  early  detection  of  dysplasia  and
colorectal cancer.  COX-2  and  p53 can  be promising  chemotherapeutic/chemopreventive
targets  in UC patients.
di  Socie©  2016  Sau
. IntroductionUlcerative colitis (UC) is a chronic, idiopathic inﬂam-
atory disorder of the large intestine that is characterized
y mucosal inﬂammation of the rectum, which extends
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proximally through the colon in a continuous manner
but to a variable extent [1]. Although the exact cause
of UC remains undetermined, the condition appears to
be related to a combination of genetic and environmen-
tal factors. Diagnosis of UC is based on a combination
of laboratory, endoscopic, histological, and radiographic
investigations [2]. Chronic UC is associated with six- to
sevenfold increased risk of colorectal cancer [3]. The risk
of developing cancer, or its precursor lesion dysplasia,
ghts reserved.
oscopy and Ultrastructure 4 (2016) 195–202
Table 1
Ulcerative Colitis Colonoscopic Index of Severity.
Score Deﬁnition
Vascular pattern
0 Normal, clear vascular pattern
1 Partially visible vascular pattern
2  Complete loss of vascular pattern
Granularity
0  Normal, smooth, and glistening
1  Fine
2 Coarse
Ulceration
0 Normal, no erosion or ulcer
1  Erosions or pinpoint ulcerations
2  Numerous shallow ulcers with mucopus
3 Deep, excavated ulcerations
4  Diffusely ulcerated with >30% involvement
Bleeding/friability
0  Normal, no bleeding, no friability
1  Friable, bleeding to light touch
2  Spontaneous bleeding
Grading of SAES and GAES
0 Normal/quiescent: visible vascular pattern
with no bleeding, erosions, ulcers or friability
(includes altered vascular pattern in quiescent
disease)
1  Mild: erythema, decreased or loss of vascular
pattern, ﬁne granularity, but no friability or
spontaneous bleeding
2  Moderate: friability with bleeding to light
touch, coarse granularity, erosions or pinpoint
ulcerations
3  Severe: spontaneous bleeding or gross ulcers196 N.M. Elmashad et al. / Journal of Micr
increases exponentially with the duration of the disease
[4].
Cyclooxygenase (COX) is an enzyme important for the
synthesis of prostaglandins. Cyclooxygenase-2 (COX-2) is
highly inducible in response to cellular activation by hor-
mones, proinﬂammatory cytokines, growth factors, and
tumor promoters [5]. COX-2 activates procarcinogens, pro-
motes angiogenesis, and indirectly increases free radical
production [6].
The tumor-suppressor gene p53 is a nuclear protein
involved in the control of the cell cycle, apoptosis, and the
maintenance of genomic stability [7]. P53 plays an active
role in both DNA repair and induction of apoptosis. It is
mutated in a variety of cancers including colorectal car-
cinoma (CRC) [8]. Abnormal p53 expression, detected by
immunohistochemistry, is often used as a marker of p53
mutation and thus found in dysplastic or cancerous tis-
sue. Repeated and continuous inﬂammation and oxidative
stress induce activation and overload of the p53 checkpoint
system, possibly resulting in p53 mutation. In patients with
UC, increased proliferation of epithelial cells and overex-
pression of p53 predispose the bowel mucosa to dysplasia
and the development of carcinoma [9].
1.1. Aim of the work
The aim of this work was to analyze the immunoex-
pression of proinﬂammatory enzyme COX-2 and p53 in
UC, UC-associated dysplasia, and CRC, in comparison with
each other and with different clinical and histopathologi-
cal parameters, to clarify if they have a possible role in the
pathogenesis of CRC in UC patients.
2. Materials and methods
In this cross-sectional study, the participants com-
prised 98 adult patients, who were prospectively recruited
from the Departments of Tropical Medicine and Infectious
Diseases and Clinical Oncology, Tanta University, Tanta,
Egypt. All participants provided informed consent, and the
study was approved by Tanta University Ethical Commit-
tee. Besides, 10 participants had functional symptomatic
irritable bowel and were diagnosed as having healthy
endoscopic and histopathological colonic ﬁndings served
as control group.
All patients were subjected to full history taking
and thorough clinical examination. Laboratory investiga-
tions, including complete blood pictures, liver function
tests, Erythrocyte Sedimentation Rate (ESR), blood urea
and serum creatinine, and stool analysis, were per-
formed to exclude bacterial causes of colitis. Radiological
investigations included plain X-ray of the abdomen
and pelviabdominal ultrasound. Colonoscopy was done
for all patients, and multiple biopsies were taken for
histopathological and immunohistochemical procedures.
The endoscopic assessment of UC severity was performed
using the Ulcerative Colitis Colonoscopic Index of Severity
(UCCIS). The vascular pattern, ulcerations, bleeding friabil-
ity, and granularity were used to obtain the UCCIS [10]
(Table 1).The GAES also includes a 10-cm visual analog scale of severity.
GAES = global assessment of endoscopic severity; SAES = segmental
assessment of endoscopic activity.
Biopsies taken during colonoscopy were ﬁxed in 10%
formaldehyde for a period of 24–48 hours, embedded in
parafﬁn, and then sectioned together with control blocks
at 3–4 m for histopathological and immunohistochemical
studies.
Endoscopy and microscopic examination of collected
biopsies allowed the grouping and classiﬁcation of studied
cases into four groups:
Group I: 39 UC patients without dysplasia
Group II: 32 UC patients with dysplasia
Group III: 27 patients with CRC on top of UC
Group IV: 10 individuals as the control group. They
underwent colonoscopy in the Endoscopy Unit at the
Tropical Medicine and Infectious Diseases department,
which revealed healthy endoscopic and histopathological
ﬁndings
Immunohistochemistry staining was  performed using
the Lab Vision’s Ultra Vision Detection Kit (TP-015-HD, Fre-
mont, CA 94539, USA), according to the manufacturer’s
protocol. Sections were incubated for 10 minutes using
Ultra V block to prevent nonspeciﬁc background staining,
followed by rinsing the sections with Phosphate Buffered
Saline (PBS). Afterward, overnight incubation was done
in a humidity chamber with rabbit polyclonal antibody
against COX-2 (Lab Vision Catalog # RB-9072-R7, Fremont,
CA 94539, USA) and mouse monoclonal antibody against
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Table  2
Demographic data of all studied groups.
Patient data Ulcerative colitis without
dysplasia (n = 39)
Ulcerative colitis with
dysplasia (n = 32)
Colorectal carcinoma on top of
ulcerative colitis (n = 27)
p
n % n % n %
Sex: male 21 54 15 47 18 67 0.307
Clinical presentation 5 13 4 13 7 26 0.284
Fever  6 15 5 16 4 15 0.975
Abdominal pain 16 41 18 56 16 59 0.267
Tenesmus and\or diarrhea 7 18 9 28 6 22 0.593
Extraintestinal manifestation
Age 38.2 ± 11 45.6 ± 9 49.5 ± 16 0.001
 3.87 
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SR = Erythrocyte Sedimentation Rate.
53 (Lab Vision p53 Ab-8, clone DO-7, Fremont, CA 94539,
SA at 1:100 dilution), followed by washing in PBS. Finally,
ections were counterstained using Mayer’s hematoxylin,
ehydrated in alcohol, and mounted in Distyrene, Plas-
icizer, and Xylene (DPX). Negative controls had primary
ntibody replaced by buffer.
.1. Scoring methods
.1.1. COX-2 scoring
COX-2 was expressed as granular cytoplasmic staining.
OX-2 reactivity was evaluated according to staining inten-
ity, which was graded as 1 (weak), 2 (moderate), or 3
strong), and the positively stained area, which was graded
s 0 (<10%), 1 (10–40%), 2 (40–70%), and 3 (≥70%). Both
arameters were evaluated in the cytoplasm of epithelial
nd inﬂammatory cells. Total scores for grade and stained
rea of ≥ 3 were deﬁned as positive and those of < 3 as
egative [11].
.1.2. P53 scoring
Positive tumor cells were quantiﬁed and expressed as
he percentage of the total number of tumor cells. The pres-
nce of p53 mutation (p53 positivity) was deﬁned as ≥ 50%
f tumor cells with unequivocal moderate/strong nuclear
taining, as recommended for improved speciﬁcity. The
bsence of p53 mutation (p53 negativity) was deﬁned as
able 3
omparison of COX-2 expression of patients in the studied groups.
COX-2 Control
(n = 10)
Ulcerative colitis without
dysplasia (n = 39)
Negative 7 20 
Positive 3 19 
X2
p  
p1 
p2  
p3 
: comparing the difference in frequencies between the four groups.
1: control and ulcerative colitis without dysplasia.
2: control and ulcerative colitis with dysplasia.
3: control and colorectal carcinoma on top of ulcerative colitis.
* Signiﬁcant.
OX-2 = cyclooxygenase-2.8 ± 4.77 0.003
64 ± 8.99 <0.001
either absent/weak staining or < 50% of tumor cells with
moderate/strong staining [12].
2.2. Statistical analysis
The collected data were organized, tabulated, and sta-
tistically analyzed using SPSS software statistical computer
package, Version 19. Analysis of variance (ANOVA) was
used to test the difference between more than two  groups;
also Dunnett test was used to compare the other groups
with the control group. Spearman correlation test was  used
to test the correlation between different variables. Signiﬁ-
cance was  adopted at p < 0.05 for interpretation of results
of tests of signiﬁcance.
3. Results
This study included 108 participants distributed into
four groups. Group I included 39 UC patients without dys-
plasia (21 male patients and 18 female patients, with a
mean age of 38.2 ± 11 years). Group II included 32 UC
patients with dysplasia (15 male patients and 17 female
patients, with a mean age of 45.6 ± 9 years). Group III
included 27 patients with UC with colorectal cancer (18
male patients and 9 female patients, with a mean age
of 49.5 ± 16 years). Group IV (control) included 10 age-
matched healthy individuals (6 male individuals and 4
female individuals, with a mean age of 40.3 ± 15.2 years).
The demographic and clinical data are shown in Table 2.
Ulcerative colitis with
dysplasia (n = 32)
Colorectal carcinoma on top of
ulcerative colitis
(n = 27)
7 6
25 21
20.737
<0.0001*
0.155
0.002*
0.009*
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Table  4
Comparison of p53 expression of patients in the studied groups.
p53 Control
(n = 10)
Ulcerative colitis without
dysplasia (n = 39)
Ulcerative colitis with dysplasia
(n = 32)
Colorectal carcinoma on top of
ulcerative colitis
(n = 27)
Negative 7 21 8 7
Positive 3 18 24 20
X2 10.721
p  0.017*
p1 0.482
p2 0.02*
p3 <0.023*
p: comparing the difference in frequencies between the four groups.
p1: control and ulcerative colitis without dysplasia.
p2: control and ulcerative colitis with dysplasia.
p3: control and colorectal carcinoma on top of ulcerative colitis.
* Signiﬁcant.
Colonoscopic examination showed a signiﬁcant differ-
ence between the three studied patient groups with respect
to an endoscopic scoring system (UCCIS) for UC (p = 0.001).
There was a signiﬁcant difference between the four
studied groups as regards COX-2 (p < 0.001), as demon-
strated in Table 3. On comparing the control group with
the other three groups, it had no signiﬁcant difference with
Group I, whereas it was signiﬁcantly different from the
other two groups, which had UC associated with dysplasia
Figure 1. Comparison of the immunohistochemical pattern of COX-2 between: (a
the  UC group, that shows strong cytoplasmic staining in epithelial cells and inﬂam
COX-2 = cyclooxygenase-2; UC = ulcerative colitis.(Group II) and UC with CRC (Group III) (0.661, <0.001, and
<0.001, respectively) as shown in Table 3. Figures 1 and 2
demonstrate COX-2 expression in the different studied
groups.
As regards p53 expression, there was a signiﬁcant
difference (p < 0.001) between the four studied groups
(Table 4). The control group differed signiﬁcantly from
the UC-associated dysplasia and CRC groups, but showed
no statistically signiﬁcant difference from the UC group
) the control, that shows weak cytoplasmic epithelial staining; and (b, c)
matory cells. (Immunoperoxidase: 400×).
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Uigure 2. Proﬁle of COX-2 in colorectal cancer on top of UC showing diffus
mmunoperoxidase.
OX-2 = cyclooxygenase-2; UC = ulcerative colitis.
ithout dysplasia. Expression of p53 in the different stud-
ed groups is demonstrated in Figures 3 and 4.
There was a signiﬁcant negative relationship between
53 and index of severity by colonoscopy, and a signiﬁcant
ositive relationship between p53 and duration of illness
n years and COX-2 expression (r = 0.2, 0.08, and 0.021; and
 = 0.04, 0.01, and 0.001, respectively).
. DiscussionPatients with Inﬂammatory Bowel Disease (IBD), both
lcerative Colitis (UC) and Crohn’s Disease (CD), are at
ncreased risk of developing CRC. In fact, IBD ranks among
igure 3. P53 immunohistochemical expression is: (a) absent in control, (b) infreq
Immunoperoxidase: 400× in (a, b, d) & 100× in (c)].
C = ulcerative colitis. cytoplasmic staining in neoplastic epithelial cells. (a) 100× and (b) 400×
the top three high-risk conditions for CRC, together with
hereditary polyposis and nonpolyposis CRC [13]. UC is a
chronic disease characterized by diffuse mucosal inﬂam-
mation limited to the colon. It involves the rectum, and
may  extend proximally in a symmetrical, circumferential,
and interrupted pattern to involve parts or all of the large
intestine [14]. The overall incidence of CRC among UC
patients is 3.7%, and this incidence increased to reach up
to 4.5% in UC patients with pancolitis [15]. UC develops
in relatively young adults, and long-term, continuous drug
therapy is required to stabilize the disease. However, a sub-
stantial number of patients are unable to strictly comply
with drug therapy during follow up, increasing the risk of
uent in UC without dysplasia, and (c, d) very frequent in UC with dysplasia.
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ar stainiFigure 4. Photomicrographs showing (a) negative and (b) positive nucle
(Immunoperoxidase: 400×).
UC = ulcerative colitis.
relapse [16]. All patients with UC should have a surveillance
colonoscopy every 1–3 years, starting 7–10 years after dis-
ease onset [17]. Random biopsies (quadrant biopsies every
10 cm)  and targeted biopsies of any visible lesion should be
performed if white light endoscopy is used [18]. The aim of
our study was to analyze the immunoexpression of proin-
ﬂammatory enzyme COX-2 and p53 in UC, UC-associated
dysplasia, and CRC, in comparison with each other and with
different clinical and histopathological parameters, to clar-
ify if they have a possible role in pathogenesis of CRC in UC
patients. Colonoscopic examination showed a signiﬁcant
difference between the three studied groups, according to
an endoscopic scoring system for UC [10] (p = 0.001). As
regards the colonoscopic severity index, there were signif-
icant differences between patients with UC with dysplasia
and those without dysplasia, indicating that there is a direct
correlation between the index of colonoscopic severity and
the degree of UC-associated dysplasia. These ﬁndings were
in concordance with the results of Kiran et al. [19], who
concluded that most UC-related CRCs can be diagnosed or
suspected on the basis of endoscopic ﬁndings and biopsy of
areas of colitis. UC-associated colorectal carcinogenesis is
believed to follow a multistep process from inﬂammation
and epithelial regeneration to hyperplastic epithelium to
ﬂat dysplasia and ﬁnally to invasive adenocarcinoma [20].
In this study, patients with CRC on top of dysplasia
(Group III) show a signiﬁcant difference from the other
groups with respect to older age but no signiﬁcant differ-
ence in UC-related dysplasia, and this was supported by
a Japanese study conducted by Watanabe et al. [21] and
another by Sanchez et al. [22], who concluded that demo-
graphic data are nonsigniﬁcant variables in UC-related
dysplasia. As regards the occurrence of carcinoma on top of
dysplasia in this study at a mean age (49.5 ± 16), Eaden et al.
[23] published a meta-analysis, reporting that the cumula-
tive risk of CRC in patients with UC was 2% at 10 years,
8% at 20 years, and 18% at 30 years. This meta-analysis
and other studies showed that the risk of developing CRC
in UC patients is increased by speciﬁc factors, such as
disease duration, extensive mucosal involvement, and con-
comitant primary sclerosing cholangitis [24]. In our study,ng for p53 protein in two cases of colonic adenocarcinoma on top of UC.
patients with CRC on top of dysplasia (Group III) showed a
statistically signiﬁcantly low pretherapy hemoglobin level
(8 ± 4.77 mg/dL) compared with the other groups; this fact
was  explained as early iron-deﬁciency anemia and has
long been recognized as a feature of colorectal cancer [25].
It is present in 11–57% of cancers [26] and is particu-
larly suggestive of cecal tumors [27]. Patients with anemia
as their presenting feature of cancer have worse staging
[28] and mortality [29]. In our work, the expression of
COX-2, especially in lamina propria, was signiﬁcantly dif-
ferent in the UC with dysplasia group (Group II) and UC
with colorectal cancer group (Group III) from the UC with-
out dysplasia and control group. COX-2 immunostaining,
according to our work, was intense in cases with dyspla-
sia with or without cancer, and the intensity is directly
correlated with the degree of dysplasia. This was sup-
ported by the study of Svec et al. [30], which concluded
that COX-2 was  signiﬁcantly increased during neoplastic
transformation of UC patients’ colonic mucosa. In concord-
ance with these were the results of Shaker et al. [31], who
concluded that COX-2 may  play a role in the pathophysi-
ological process of inﬂammatory bowel disease and in the
development of carcinoma. Thus, it can be used as a marker
for premalignant and malignant lesions. They added that
COX-2 inhibitors can be used in the targeted therapy of
these lesions [31]. Fratila and Ilias [32] found that COX-2
immunostaining was positive in UC-related dysplasia cases
and negative in nondysplastic cases, which is supported
by our results. Interestingly, by contrast, in the study of
Agoff et al. [33], COX-2 overexpression occurred early in
UC-associated neoplasia; however, the cancer risk increase
could not be explained solely by inﬂammatory activity. In
their study, the overall neoplastic change explained the
majority of the variation in COX-2 expression, whereas
inﬂammatory activity explained only 11%.
As regards p53, our study showed that there was a sig-
niﬁcant difference in the expression of p53 between the
UC-related dysplasia group (Group II) and CRC on top of UC
group (Group III) and the UC group without dysplasia group
(Group I) and control group. These results were supported
by Kulaylat and Dayton [34], who studied the difference
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etween sporadic CRC and UC-related CRC, with respect to
istological abnormalities and genetic alterations, and they
oncluded that there is an early expression of p53 in UC-
elated CRC and late expression in sporadic CRC. Another
tudy by Vaji et al. [35] in 2011, concluded that genetic
olymorphism of p53 is closely related to UC and subse-
uently to dysplasia. In concordance with our results are
he results of the study by Risques et al. [36] in 2011, who
oncluded that the expression of p53 was low in nondys-
lastic biopsies, but progressively increased in low- and
igh-grade dysplasia. Surprisingly, a high p53 expression
as been found in chronic UC patients with severe dis-
ase but without cancer [37]. The inﬂammatory cells in UC
enerate oxygen radicals and nitrogen species, which lead
o oxidative stress and genetic alterations involved in cell
epair leading to dysplasia and hence to CRC [4].
Our study showed a signiﬁcant negative relationship
etween p53 and the index of severity by colonoscopy, and
 signiﬁcant positive relationship between p53 and dura-
ion of illness in years and COX-2 expression (r = 0.2, 0.08,
nd 0.021; and p = 0.04, 0.01, and 0.001, respectively). COX-
 expression has previously been shown to be repressed
y wild-type p53 [38], although p53 is unlikely the only
egulator of COX-2. Thus, tumors with wild-type p53 may
ave a lower frequency of COX-2 overexpression. Indeed,
ur data support this hypothesis. The frequency of COX-2–
umors was higher among p53– tumors than among p53+
umors, and COX-2 and p53 statuses were positively corre-
ated with each other. For therapeutic approaches targeting
he COX-2 pathway, it may  be important to consider the
ffects of wild-type or mutant p53, potentially modulating
ignaling through the COX-2 pathway. Further study is nec-
ssary to investigate the mechanisms of COX-2 regulation
y p53.
The apparent synergistic effect of COX-2 and p53 might
lso reﬂect the limitations of immunohistochemical assays
n which false positives and false negatives can occur, and
he combined analysis for COX-2 and p53 might select
umors that are caused by COX-2 activation, which can,
n turn, be caused by mutations and functional loss of
53. It has been shown that the correlation between TP53
ene mutations and p53 positivity by immunohistochem-
stry is less than perfect [39]. Thus, the combination of
OX-2 and p53 immunohistochemistry might be useful to
ecrease false positives and false negatives, or to select a
ore homogenous group of colorectal cancer cases. COX-
 expression has been shown to be regulated by wild-type
53, suggesting that TP53 mutation may  cause deregulation
f COX-2 expression [38]. Previous studies demonstrated
hat MSI-H tumors, whether in sporadic or in familial set-
ing, are inversely associated with COX-2 overexpression
40]. In addition, Ogino et al. [41] in 2006 suggested a syn-
rgistic effect of CpG island methylator phenotype (CIMP)
nd microsatellite instability—high (MSI-H) on lowering
he frequency of COX-2 and p53 overexpression in colorec-
al cancer. Elucidating the molecular mechanisms of COX-2
verexpression and its action in COX-2-overexpressed
umors, and the alternative mechanisms that may  bypass
OX-2 overfunction in COX-2– tumors is important for
he purpose of developing molecularly targeted treatments
gainst colorectal cancer [42].
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Our data may  have signiﬁcant clinical implications
because of the emerging importance of both COX-2 and p53
as promising chemotherapeutic/chemopreventive targets.
The present study carries two  messages that we believe to
be important. First, COX-2 is an attractive chemopreventive
target [43]. The COX inhibitor aspirin has been known to
decrease the risk for colorectal cancer [44], and the more
recent COX-2-speciﬁc inhibitor celecoxib has been shown
to inhibit the growth of colorectal cancer cells in vitro [45],
especially for young patients having UC with dysplasia, to
avoid developing cancer in their future lifetime. The second
message is for the patients with colorectal cancer harboring
COX-2 overexpression who  should receive molecular tar-
get therapy in their adjuvant setting. However, our study
had several limitations: it was conducted in a single center
and had a small sample size. Further multicenter prospec-
tive studies with larger numbers of patients are needed to
conﬁrm our ﬁndings and to further delineate the clinical
signiﬁcance of COX-2 expression in UC.
5. Conclusion
Adding immunohistochemical analysis of COX-2
enzyme and p53 gene to routine histological assessment
may  improve the accuracy of early detection of dysplasia
and colorectal cancer. COX-2 and p53 can be promis-
ing chemotherapeutic/chemopreventive targets in UC
patients.
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